A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Clinical trial NCT04540705 · COMPLETED
Trial details
- NCT number
- NCT04540705
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-11
- Primary completion
- 2024-01-18
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.